BioXcel Therapeutics (BTAI) Insider Trading & Ownership $0.59 -0.01 (-1.67%) (As of 11/20/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioXcel Therapeutics (NASDAQ:BTAI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage28.70%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$234,910.45 Get BTAI Insider Trade Alerts Want to know when executives and insiders are buying or selling BioXcel Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BTAI Insider Buying and Selling by Quarter Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. BioXcel Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/3/2024Matthew T WileyInsiderSell6,272$0.55$3,449.60 10/3/2024Richard I SteinhartCFOSell7,175$0.55$3,946.25 9/16/2024Frank YoccaInsiderSell355$0.69$244.95 9/16/2024Richard I SteinhartCFOSell356$0.69$245.64 9/16/2024Vimal MehtaCEOSell1,982$0.69$1,367.58 6/17/2024Frank YoccaInsiderSell372$1.28$476.16 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/17/2024Vimal MehtaCEOSell2,134$1.28$2,731.52 6/4/2024Vimal MehtaCEOSell126,014$1.63$205,402.82 4/4/2024Richard I SteinhartCFOSell1,069$2.63$2,811.47 4/4/2024Vimal MehtaCEOSell5,268$2.62$13,802.16 4/4/2024Vincent O'neillInsiderSell165$2.62$432.30 (Data available from 1/1/2013 forward) BTAI Insider Trading Activity - Frequently Asked Questions Who is on BioXcel Therapeutics's Insider Roster? The list of insiders at BioXcel Therapeutics includes Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Matthew T Wiley, Richard I Steinhart, Vimal Mehta, and Vincent O'neill. Learn more on insiders at BTAI. What percentage of BioXcel Therapeutics stock is owned by insiders? 28.70% of BioXcel Therapeutics stock is owned by insiders. Learn more on BTAI's insider holdings. Which BioXcel Therapeutics insiders have been selling company stock? The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,520,115.76), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($1,617,560.26), Matthew T Wiley ($3,449.60), Richard I Steinhart ($183,491.36), Vimal Mehta ($2,252,379.08), and Vincent O'neill ($432.30). How much insider selling is happening at BioXcel Therapeutics? Insiders have sold a total of 397,905 BioXcel Therapeutics shares in the last 24 months for a total of $5,626,194.56 sold. BioXcel Therapeutics Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, President, & Director Compensation: $1.76MMr. Javier Rodriguez (Age 51)Senior VP, Chief Legal Officer & Corporate Secretary Compensation: $638.88kMr. Matthew Wiley (Age 51)Senior VP & Chief Commercial Officer Compensation: $620.12k1 recent tradesMr. Richard I. Steinhart MBA (Age 67)Senior VP & CFO Compensation: $404k2 recent tradesDr. Frank D. Yocca Ph.D. (Age 67)Senior VP & Chief Scientific Officer Compensation: $452.58kDr. Vincent J. O'Neill B.Sc. (Age 55)M.D., M.R.C.P., Executive VP and Chief of Product Development & Medical Officer Compensation: $510.17kDr. Chetan D. Lathia Ph.D.Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - Neuroscience More Insider Trading Tools from MarketBeat Related Companies Anixa Biosciences Insider Selling Monopar Therapeutics Insider Selling Nuvectis Pharma Insider Selling Karyopharm Therapeutics Insider Selling Eliem Therapeutics Insider Selling Coherus BioSciences Insider Selling Immunic Insider Selling MediciNova Insider Selling Assertio Insider Selling Generation Bio Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:BTAI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
